Zobrazeno 1 - 10
of 109
pro vyhledávání: ''
Autor:
Dongsheng Tu, Timothy J. Price, Hagen F. Kennecke, Daniel L. Edelstein, Scott Kopetz, Frank Holtrup, Hannah Quinn, Anthony Dowers, Stanley R. Hamilton, Derek J. Jonker, John Zalcberg, Christos S Karapetis, Paul Waring, Jonathan M. Loree, Christopher J. O'Callaghan, Malcolm J. Moore
Publikováno v:
Clinical Cancer Research. 27:52-59
Purpose: Expanded RAS/BRAF mutations have not been assessed as predictive for single-agent cetuximab in metastatic colorectal cancer (mCRC), and low mutant allele frequency (MAF) mutations are of unclear significance. We aimed to establish cetuximab
Autor:
Jan H. Beumer, Huichen Feng, Ashwin Reddy Sama, Thomas J. George, Corey Lipchik, Carmen J. Allegra, Melanie Finnigan, Philip J. Stella, James L. Wade, Katherine L. Pogue-Geile, Ying Wang, Patrick G. Gavin, Ashok Srinivasan, James J. Lee, Rim S. Kim, Norman Wolmark, Brian F. Kiesel, Peter C. Lucas, Fanny Piette, Samuel A. Jacobs, Ding Wang
Publikováno v:
Clinical Cancer Research. 27:1612-1622
Purpose: In metastatic colorectal cancer (mCRC), HER2 (ERBB2) gene amplification is implicated in anti-EGFR therapy resistance. We sought to determine the recommended phase II dose (RP2D) and efficacy of neratinib, a pan-ERBB kinase inhibitor, combin
Autor:
Richard Price, Christine Ju, Johanna C. Bendell, Herbert Hurwitz, Xiaoju Max Ma, John Lee, Nalin Tikoo, Christoph Mancao, Lijing Yao, Alex Lovejoy, Alan Nicholas, Stephanie J. Yaung, John F. Palma, Nicolas Sommer
Publikováno v:
Clinical Cancer Research. 26:4010-4017
Purpose:We assessed plasma circulating tumor DNA (ctDNA) level as a prognostic marker for progression-free survival (PFS) following first-line metastatic colorectal cancer (mCRC) therapy.Experimental Design:The Sequencing Triplet With Avastin and Mai
Autor:
Michael J. Schell, Michael Nebozhyn, W. Jack Pledger, Jiannong Li, Jamie K. Teer, Mingli Yang, Timothy J. Yeatman, Andrey Loboda
Publikováno v:
Cancer Epidemiology, Biomarkers & Prevention. 28:1141-1152
Background: EGFR is a major therapeutic target for colorectal cancer. Currently, extended RAS/RAF testing identifies only nonresponders to EGFR inhibitors (EGFRi). We aimed to develop a mutation signature that further refines drug-sensitive subpopula
Autor:
Vinod Ganju, M. Karthaus, Alessio Amatu, Andrea Pirzkall, Amy V. Kapp, Michael Findlay, Maria Di Bartolomeo, Leslie Samuel, Manuel Hidalgo, Bruce McCall, Christopher Jackson, Roxana Ioana Sufan, Andrew L. Coveler, William D. Hanley, John Bridgewater, Matthew Burge, Elicia Penuel, Pilar García Alfonso, Andrew G. Hill, Josep Tabernero, Mark Jeffery
Publikováno v:
Clinical Cancer Research. 24:2276-2284
Purpose: Duligotuzumab is a dual-action antibody directed against EGFR and HER3. Experimental Design: Metastatic colorectal cancer (mCRC) patients with KRAS ex2 wild-type received duligotuzumab or cetuximab and FOLFIRI until progression or intolerabl
Autor:
Ulivi Paola, Laura Matteucci, Milena Urbini, Alessandro Passardi, Gianluca Tedaldi, Giorgia Marisi, Matteo Canale, Giovanni Martinelli, Giovanni Luca Frassineti, Chiara Molinari
Publikováno v:
Cancer Research. 81:541-541
The use of liquid biopsy in the clinical management of colorectal cancer (CRC) patients is not yet a routine clinical practice, although it could give important information for tumor baseline characterization and for monitoring during treatment. In t
Autor:
Helmout Modjtahedi, Soozana Puvanenthiran, Sharadah Essapen, Izhar Bagwan, Alan M. Seddon, Said Abdullah Khelwatty
Publikováno v:
Cancer Research. 81:350-350
Background: Overexpression of the EGFR is common in patients with a wide range of cancers and the EGFR is an important target for therapy with monoclonal antibodies (mAbs) based drugs. Of these, cetuximab and panitumumab have been approved for the tr
Publikováno v:
Cancer Research. 81:1353-1353
Background: RAS mutations are found in nearly one third of patients with cancer. As part of the Ras-Raf-MEK-ERK pathway, RAS mutations lead to uninhibited cell growth, proliferation, and survival. KRAS mutations account for a large majority of RAS mu
Autor:
Daniel I. Isaac, Ryan Ramaekers, Mark Erlander, Manish R. Sharma, Lawrence Mendelsohn, Maya Ridinger
Publikováno v:
Cancer Research. 81:425-425
Introduction: Chemotherapy in combination with targeted agents are standard-of-care options for first and second-line treatment of metastatic colorectal cancer (mCRC) patients. Second-line treatment of KRAS-mutated mCRC confers a dismal patient outco
Autor:
Luigi Formisano, Erika Martinelli, Matilde Lambiase, Francesca Fenizia, Roberto Bianco, Floriana Morgillo, Fortunato Ciardiello, Giulia Martini, Donata Vitagliano, Teresa Troiani, Claudia Cardone, Nicola Normanno, Davide Ciardiello, Stefania Napolitano
Publikováno v:
Clinical Cancer Research. 21:4153-4164
Purpose: The use of cetuximab in the treatment of metastatic colorectal cancer is limited by development of resistance. Experimental Design: We have investigated in three models of highly epidermal growth factor receptor (EGFR)–dependent colorectal